Literature DB >> 8866566

A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog.

D K Sindelar1, J H Balcom, C A Chu, D W Neal, A D Cherrington.   

Abstract

We investigated the mechanisms by which peripheral or portal insulin can independently alter liver glucose production. Isotopic ([3-3H]glucose) and arteriovenous difference methods were used in conscious overnight-fasted dogs. A pancreatic clamp (somatostatin plus basal insulin and basal glucagon infusions) was used to control the endocrine pancreas. After a 40-min basal period, a 180-min experimental period followed in which selective increases in peripheral (PERI group, n = 5) or portal-vein (PORT group, n = 5) insulin were induced. In control dogs (CONT group, n = 10), insulin was not increased. Glucagon levels were fixed in all studies, and basal euglycemia was maintained by peripheral glucose infusion in the two experimental groups. In the PERI group, arterial insulin rose from 36 +/- 12 to 120 +/- 12 pmol/l, while portal insulin was unaltered. In the PORT group, portal insulin rose from 108 +/- 42 to 192 +/- 42 pmol/l, while arterial insulin was unaltered. Neither arterial nor portal insulin changed from basal in the CONT group. With a selective rise in peripheral insulin, the net hepatic glucose output (NHGO; basal, 11.8 +/- 0.7 micromol x kg-1 x min-1) did not change initially (11.8 +/- 2.1 micromol x kg-1 x min-1, 30 min after the insulin increase), but eventually fell (P < 0.05 ) to 6.1 +/- 0.9 micromol x kg-1 x min-1 (last 30 min). With a selective rise in portal insulin, NHGO dropped quickly (P < 0.05) from 10.0 +/- 0.9 to 5.6 +/- 0.6 micromol x kg-1 x min-1 (30 min after the insulin increase) and eventually reached 3.1 +/- 1.1 micromol x kg-1 x min-1 (last 30 min). When insulin levels were not increased (CONT group), NHGO dropped progressively from 10.1 +/- 0.6 to 8.3 +/- 0.6 micromol x kg-1 x min-1 (last 30 min). Conclusions drawn from the net hepatic glucose balance data were confirmed by the tracer data. Net hepatic gluconeogenic substrate uptake (three carbon precursors) fell 2.0 micromol x kg-1 x min-1 in the PERI group, but rose 1.2 micromol x kg-1 x min-1 in the PORT group and 1.2 micromol x kg-1 x min-1 in the CONT group. A selective 84 pmol/l rise in arterial insulin was thus associated with a fall in NHGO of approximately 50%, which took 1 h to manifest. Conversely, a selective 84 pmol/l rise in portal insulin was associated with a 50% fall in NHGO, which occurred quickly (15 min). From the control data, it is evident that in either case approximately 30% of the fall in NHGO was due to a drift down in baseline and that 70% was due to the rise in insulin. In conclusion, an increment in portal insulin had a rapid inhibitory effect on NHGO, caused by the suppression of glycogenolysis, while an equal increment in arterial insulin produced an equally potent but slower effect that resulted from a small increase in hepatic sinusoidal insulin, from a suppression of gluconeogenic precursor uptake by the liver, and from a redirection of glycogenolytic carbon to lactate rather than glucose.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866566     DOI: 10.2337/diab.45.11.1594

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  46 in total

Review 1.  Insulin's effect on glucose production: direct or indirect?

Authors:  Eugene J Barrett
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

2.  Effects of long-term cranberry supplementation on endocrine pancreas in aging rats.

Authors:  Min Zhu; Jingping Hu; Evelyn Perez; Dawn Phillips; Wook Kim; Reza Ghaedian; Joshua K Napora; Sige Zou
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-07-18       Impact factor: 6.053

3.  Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia.

Authors:  S D Mittelman; Y Y Fu; K Rebrin; G Steil; R N Bergman
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

4.  Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo.

Authors:  Christopher J Ramnanan; Dale S Edgerton; Noelia Rivera; Jose Irimia-Dominguez; Ben Farmer; Doss W Neal; Margaret Lautz; E Patrick Donahue; Catalina M Meyer; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

5.  Glucagon's effect on liver protein metabolism in vivo.

Authors:  Guillaume Kraft; Katie C Coate; Jason J Winnick; Dominique Dardevet; E Patrick Donahue; Alan D Cherrington; Phillip E Williams; Mary Courtney Moore
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-23       Impact factor: 4.310

6.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

7.  The role of CCK8 in the inhibition of glucose production.

Authors:  Christopher J Ramnanan; Dale S Edgerton; Alan D Cherrington
Journal:  Cellscience       Date:  2009-10-27

Review 8.  Mechanisms of Insulin Action and Insulin Resistance.

Authors:  Max C Petersen; Gerald I Shulman
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

9.  ChREBP regulates fructose-induced glucose production independently of insulin signaling.

Authors:  Mi-Sung Kim; Sarah A Krawczyk; Ludivine Doridot; Alan J Fowler; Jennifer X Wang; Sunia A Trauger; Hye-Lim Noh; Hee Joon Kang; John K Meissen; Matthew Blatnik; Jason K Kim; Michelle Lai; Mark A Herman
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

10.  Chronic peripheral hyperinsulinemia in type 1 diabetic patients after successful combined pancreas-kidney transplantation does not affect ectopic lipid accumulation in skeletal muscle and liver.

Authors:  Marietta Stadler; Christian Anderwald; Giovanni Pacini; Stefan Zbýn; Miriam Promintzer-Schifferl; Martina Mandl; Martin Bischof; Stephan Gruber; Peter Nowotny; Anton Luger; Rudolf Prager; Michael Krebs
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.